The Inclusion of Patients’ Reported Outcomes to Inform Treatment Effectiveness Measures in Opioid Use Disorder. A Systematic Review

References

• Opioid overdose. Available from: https://www.who.int/news-room/fact-sheets/detail/opioid-overdose. Accessed April 26, 2022.
   Google Scholar
• World drug report; 2021. Available from: https://www.unodc.org/unodc/en/data-and-analysis/wdr2021.html. Accessed April 26, 2022.
   Google Scholar
• Opioid- and stimulant-related harms in Canada. Available from: https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/. Accessed November 10, 2021.
   Google Scholar
• Canadian Institute for Health Information. Opioids in Canada. Available from: https://www.cihi.ca/en/opioids-in-canada. Accessed November 10, 2021.
   Google Scholar
• Interactive Opioid Tool. Public health Ontario. Available from: https://www.publichealthontario.ca/en/data-and-analysis/substance-use/interactive-opioid-tool. Accessed November 10, 2021.
   Google Scholar
• American Psychiatric Association, American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, VA; 2013.
   Google Scholar
• CDC. Centers for Disease Control and Prevention. U.S.: State Prescribing Rates; 2016.
   Google Scholar
• Abuse S Results from the 2012 national survey on drug use and health: summary of national findings, NSDUH series H-46, HHS publication no. (SMA) 13–4795. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
   Google Scholar
• Rieb LM, Samaan Z, Furlan AD, et al. Canadian guidelines on opioid use disorder among older adults. Can Geriatr J. 2020;23(1):123. doi:10.5770/cgj.23.420
   PubMed Web of Science ®Google Scholar
• Sociodemographic Profiles and Clinical Outcomes for Clients. Journal of forensic nursing. Available from: https://journals.lww.com/forensicnursing/Abstract/2019/12000/Sociodemographic_Profiles_and_Clinical_Outcomes.8.aspx. Accessed November 10, 2021.
   Google Scholar
• Park TW, Cheng DM, Lloyd‐Travaglini CA, Bernstein J, Palfai TP, Saitz R. Changes in health outcomes as a function of abstinence and reduction in illicit psychoactive drug use: a prospective study in primary care. Addiction. 2015;110(9):1476–1483. doi:10.1111/add.13020
   PubMed Web of Science ®Google Scholar
• Darke S, Marel C, Slade T, Ross J, Mills KL, Teesson M. Patterns and correlates of sustained heroin abstinence: findings from the 11-year follow-up of the Australian Treatment Outcome Study. J Stud Alcohol Drugs. 2015;76(6):909–915. doi:10.15288/jsad.2015.76.909
   PubMed Web of Science ®Google Scholar
• Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci. 1995;245(2):114–124. doi:10.1007/BF02190738
   PubMed Web of Science ®Google Scholar
• Bawor M, Dennis BB, Varenbut M, et al. Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. Biol Sex Differ. 2015;6(1):21. doi:10.1186/s13293-015-0038-6
   PubMed Web of Science ®Google Scholar
• Zielinski L, Bhatt M, Sanger N, et al. Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences. Biol Sex Differ. 2017;8(1):8. doi:10.1186/s13293-017-0130-1
   PubMed Web of Science ®Google Scholar
• Kakko J, Grönbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164(5):797–803. doi:10.1176/ajp.2007.164.5.797
   PubMed Web of Science ®Google Scholar
• Lions C, Carrieri MP, Michel L, et al. Predictors of non-prescribed opioid use after one year of methadone treatment: an attributable-risk approach (ANRS-Methaville trial). Drug Alcohol Depend. 2014;135:1–8. doi:10.1016/j.drugalcdep.2013.10.018
   PubMed Web of Science ®Google Scholar
• Dennis BB, Sanger N, Bawor M, et al. A call for consensus in defining efficacy in clinical trials for opioid addiction: combined results from a systematic review and qualitative study in patients receiving pharmacological assisted therapy for opioid use disorder. Trials. 2020;21(1):30. doi:10.1186/s13063-019-3995-y
   PubMed Web of Science ®Google Scholar
• Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357–368. doi:10.1056/NEJMra1604339
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947–1954. doi:10.1001/jamainternmed.2014.5302
   PubMed Web of Science ®Google Scholar
• Cisewski DH, Santos C, Koyfman A, Long B. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting. Am J Emerg Med. 2019;37(1):143–150. doi:10.1016/j.ajem.2018.10.013
   PubMed Web of Science ®Google Scholar
• ScienceDirect. Considering the harms of our habits: the reflexive urine drug screen in opioid use disorder treatment. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0740547220305158. Accessed November 11, 2021.
   Google Scholar
• Centre for Addiction and Mental Health. Opioid Agonist Therapy: A Synthesis of Canadian Guidelines for Treating Opioid Use Disorder. Published May 2021. Available at https://www.camh.ca/-/media/files/professionals/canadian-opioid-use-disorder-guideline2021-pdf.pdf
   Google Scholar
• Solberg LI, Asche SE, Butler JC. It is time to ask patients what outcomes are important to them. Am J Accountable Care. 2015;3(4):48–54.
   Google Scholar
• American Geriatrics Society Expert Panel on Person-Centered Care. Person-centered care: a definition and essential elements. J Am Geriatr Soc. 2016;64(1):15–18. doi:10.1111/jgs.13866
   PubMed Web of Science ®Google Scholar
• Marsden J, Gossop M, Stewart D, et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93(12):1857–1867. doi:10.1046/j.1360-0443.1998.9312185711.x
   PubMed Web of Science ®Google Scholar
• Sanger N, Shahid H, Dennis BB, et al. Identifying patient-important outcomes in medication-assisted treatment for opioid use disorder patients: a systematic review protocol. BMJ open. 2018;8(12):e025059. doi:10.1136/bmjopen-2018-025059
   PubMed Web of Science ®Google Scholar
• Covidence. Covidence systematic review software. Melbourne: Australia. Veritas health innovation; 2019.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
   PubMed Web of Science ®Google Scholar
• Long HA, French DP, Brooks JM. Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis. Res Method Med Health Sci. 2020;1(1):31–42. doi:10.1177/2632084320947559
   Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2000.
   Google Scholar
• Sanger N, Panesar B, Rosic T, et al. The future of precision medicine in opioid use disorder: inclusion of patient-important outcomes in clinical trials. Braz J Psychiatry. 2020;43:138–146.
   Google Scholar
• Groshkova T, Metrebian N, Hallam C, et al. Treatment expectations and satisfaction of treatment‐refractory opioid‐dependent patients in RIOTT, the R andomised I njectable O piate T reatment T rial, the UK’s first supervised injectable maintenance clinics. Drug Alcohol Rev. 2013;32(6):566–573. doi:10.1111/dar.12062
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Morioka R, Reisinger HS, et al. Redefining retention: recovery from the patient’s perspective. J Psychoactive Drugs. 2011;43(2):99–107. doi:10.1080/02791072.2011.587392
   PubMed Web of Science ®Google Scholar
• Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: a qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):1–9. doi:10.1186/s13011-020-0253-y
   PubMed Web of Science ®Google Scholar
• Stöver H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011;17(1):44–54. doi:10.1159/000320576
   PubMed Web of Science ®Google Scholar
• O’Reilly F, O’Connell D, O’Carroll A, Whitford DL, Long J. Sharing control: user involvement in general practice based methadone maintenance. Ir J Psychol Med. 2011;28(3):129–133. doi:10.1017/S079096670001209X
   PubMedGoogle Scholar
• Dale-Perera A, Alam F, Barker P. Opioid-dependence treatment in the era of recovery: insights from a UK survey of physicians, patients and out-of-treatment opioid users. J Subst Use. 2015;20(5):354–362. doi:10.3109/14659891.2014.923532
   Web of Science ®Google Scholar
• Gelpi-Acosta C. Challenging biopower:“Liquid cuffs” and the “Junkie” habitus. Drugs. 2015;22(3):248–254.
   Web of Science ®Google Scholar
• Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70. doi:10.1016/S0140-6736(11)61138-0
   PubMed Web of Science ®Google Scholar
• Rosic T, Naji L, Bawor M, et al. The impact of comorbid psychiatric disorders on methadone maintenance treatment in opioid use disorder: a prospective cohort study. Neuropsychiatr Dis Treat. 2017;13:1399–1408. doi:10.2147/NDT.S129480
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2006;82(3):211–217. doi:10.1016/j.drugalcdep.2005.09.004
   PubMed Web of Science ®Google Scholar
• Zador D, Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990–1995. Addiction. 2000;95(1):77–84. doi:10.1046/j.1360-0443.2000.951778.x
   PubMed Web of Science ®Google Scholar
• Huang CLC, Lee CW. Factors associated with mortality among heroin users after seeking treatment with methadone: a population-based cohort study in Taiwan. J Subst Abuse Treat. 2013;44(3):295–300. doi:10.1016/j.jsat.2012.08.003
   PubMed Web of Science ®Google Scholar
• Dennis BB, Roshanov PS, Naji L, et al. Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. Trials. 2015;16(1):1–18. doi:10.1186/s13063-015-0942-4
   PubMed Web of Science ®Google Scholar
• Kosten TR, Baxter LE. Effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55–62. doi:10.1111/ajad.12862
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253–259. doi:10.1080/02791072.2003.10400007
   PubMed Web of Science ®Google Scholar
• Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340–352. doi:10.1016/j.jsat.2010.07.009
   PubMed Web of Science ®Google Scholar
• Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358. doi:10.1097/ADM.0000000000000166
   PubMed Web of Science ®Google Scholar
• Abuse S. Medications for opioid use disorder. Treatment Improvement Protocol (TIP) series 63, executive summary. HHS Publication No. (SMA) 18-5063EXSUMM; 2018.
   Google Scholar
• Cousins G, Boland F, Courtney B, Barry J, Lyons S, Fahey T. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study. Addiction. 2016;111(1):73–82. doi:10.1111/add.13087
   PubMed Web of Science ®Google Scholar
• Sanger N, Bhatt M, Shams I, et al. Association between socio-demographic and health functioning variables among patients with opioid use disorder introduced by prescription: a prospective cohort study. Pain Physician. 2018;21(6):E623–E632.
   PubMed Web of Science ®Google Scholar
• Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26–30. doi:10.1016/j.jsat.2017.03.006
   PubMed Web of Science ®Google Scholar
• Abuse NI on D. As opioid use disorders increased, prescriptions for treatment did not keep pace. National Institute on Drug Abuse. Published July 2; 2018. Available from: https://www.drugabuse.gov/news-events/nida-notes/2018/07/opioid-use-disorders-increased-prescriptions-treatment-did-not-keep-pace. Accessed November 21, 2021.
   Google Scholar
• Halkitis PN, Parsons JT. Recreational drug use and HIV-risk sexual behavior among men frequenting gay social venues. J Gay Lesbian Soc Serv. 2002;14(4):19–38. doi:10.1300/J041v14n04_02
   Google Scholar
• Anokye NK, Trueman P, Green C, Pavey TG, Taylor RS. Physical activity and health related quality of life. BMC Public Health. 2012;12(1):624. doi:10.1186/1471-2458-12-624
   PubMed Web of Science ®Google Scholar
• Carpentier PJ, Krabbe PFM, van Gogh MT, Knapen LJM, Buitelaar JK, de Jong CAJ. Psychiatric comorbidity reduces quality of life in chronic methadone maintained patients. Am J Addict. 2009;18(6):470–480. doi:10.3109/10550490903205652
   PubMed Web of Science ®Google Scholar
• Brooner RK, Kidorf MS, King VL, et al. Managing psychiatric comorbidity within versus outside of methadone treatment settings: a randomized and controlled evaluation. Addiction. 2013;108(11):1942–1951. doi:10.1111/add.12269
   PubMed Web of Science ®Google Scholar
• Bruneau J, Ahamad K, Goyer MÈ, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190(9):E247–E257. doi:10.1503/cmaj.170958
   PubMed Web of Science ®Google Scholar
• Rhee TG, Rosenheck RA. Association of current and past opioid use disorders with health-related quality of life and employment among US adults. Drug Alcohol Depend. 2019;199:122–128. doi:10.1016/j.drugalcdep.2019.03.004
   PubMed Web of Science ®Google Scholar
• Walton MT, Hall MT. The effects of employment interventions on addiction treatment outcomes: a review of the literature. J Soc Work Pract Addict. 2016;16(4):358–384. doi:10.1080/1533256X.2016.1235429
   Web of Science ®Google Scholar
• Richardson L, Wood E, Montaner J, Kerr T. Addiction treatment-related Employment barriers: the impact of methadone maintenance. J Subst Abuse Treat. 2012;43(3):276–284. doi:10.1016/j.jsat.2011.12.008
   PubMed Web of Science ®Google Scholar
• Murphy SM, Polsky D, Lee JD, et al. Cost‐effectiveness of extended release naltrexone to prevent relapse among criminal justice‐involved individuals with a history of opioid use disorder. Addiction. 2017;112(8):1440–1450. doi:10.1111/add.13807
   PubMed Web of Science ®Google Scholar
• Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Methadone dose and treatment outcome. Drug Alcohol Depend. 1993;33(2):105–117. doi:10.1016/0376-8716(93)90052-R
   PubMed Web of Science ®Google Scholar
• Zhou K, Zhuang G. Retention in methadone maintenance treatment in mainland China, 2004–2012: a literature review. Addict Behav. 2014;39(1):22–29. doi:10.1016/j.addbeh.2013.09.001
   PubMed Web of Science ®Google Scholar
• Wasserman DA, Stewart AL, Delucchi KL. Social support and abstinence from opiates and cocaine during opioid maintenance treatment. Drug Alcohol Depend. 2001;65(1):65–75. doi:10.1016/S0376-8716(01)00151-X
   PubMed Web of Science ®Google Scholar
• Lobmaier P, Gossop M, Waal H, Bramness J. The pharmacological treatment of opioid addiction - A clinical perspective. Eur J Clin Pharmacol. 2010;66(6):537–545. doi:10.1007/s00228-010-0793-6
   PubMed Web of Science ®Google Scholar
• Page M, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi:10.1136/bmj.n71
   Web of Science ®Google Scholar